Dr. Reddy's Laboratories Limited (BOM:500124)

Dr. Reddy's Laboratories Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	331,186	335,933	325,535	279,164	245,879	214,391
Revenue Growth	-0.92%	3.19%	16.61%	13.54%	14.69%	13.00%
Gross Profit Gross Profit Growth	166,177	177,264	190,428	163,607	139,343	113,840
Operating Income Operating Income Growth	35,162	49,246	72,014	65,308	53,416	35,919
Net Income Net Income Growth	33,107	42,850	56,544	55,684	45,067	23,568
Earnings Per Share EPS Growth	39.72	51.42	67.78	66.80	54.17	28.34
EPS Growth	-41.68%	-24.14%	1.47%	23.32%	91.16%	36.70%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Others Others Growth	669	2,127	2,137	3,910	3,042	4,481
Pharmaceutical Services and Active Ingredients (PSAI) Pharmaceutical Services and Active Ingredients (PSAI) Growth	42,861	42,043	43,235	40,580	36,518	36,995
Global Generics Global Generics Growth	295,406	299,033	289,552	245,453	213,768	179,170
Inter-Segment Revenues Inter-Segment Revenues Growth	-7,750	-7,270	-9,389	-10,779	-7,449	-6,255
Total Total Growth	331,186	335,933	325,535	279,164	245,879	214,391

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	81,427	87,814	57,908	81,470	61,797	44,365
Total Debt Total Debt Growth	71,952	77,341	46,766	20,020	13,472	33,845
Net Cash (Debt) Net Cash Growth	9,475	10,473	11,142	61,450	48,325	10,520
Net Cash Growth	-47.49%	-6.00%	-81.87%	27.16%	359.36%	146.66%
Net Cash Per Share Net Cash Per Share Growth	11.37	12.57	13.36	73.72	58.09	12.65

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	41,199	56,755	46,428	45,433	58,875	28,108
Capital Expenditures CapEx Growth	-19,891	-23,326	-27,504	-16,403	-11,323	-14,660
Free Cash Flow Free Cash Flow Growth	21,308	33,429	18,924	29,030	47,552	13,448
Free Cash Flow Growth	-8.57%	76.65%	-34.81%	-38.95%	253.60%	-48.20%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	50.18%	52.77%	58.50%	58.61%	56.67%	53.10%
Operating Margin	10.62%	14.66%	22.12%	23.39%	21.73%	16.75%
Pretax Margin	12.47%	16.32%	23.59%	25.74%	24.55%	15.06%
Profit Margin	10.00%	12.76%	17.37%	19.95%	18.33%	10.99%
FCF Margin	6.43%	9.95%	5.81%	10.40%	19.34%	6.27%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 2, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	8.000	8.000	8.000	8.000	8.000	6.000
Dividend Per Share Growth	0%	0%	0%	0%	33.33%	20.00%
Dividend Yield	0.70%	0.64%	0.71%	0.66%	0.89%	0.72%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 2, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	28.89	24.38	16.86	18.41	17.03	30.32
Forward PE	25.35	21.35	15.36	19.12	19.56	23.75
P/FCF Ratio	44.86	31.25	50.37	35.31	16.14	53.13
PS Ratio	2.89	3.11	2.93	3.67	3.12	3.33

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error